AI Generated Image
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Biogen • • business
Key Points:
- Biogen Inc. has agreed to acquire RayThera Inc., a biotechnology company specializing in small molecule immunology therapies, for up to $1 billion, including upfront and milestone payments.
- RayThera’s portfolio features multiple anti-inflammatory assets targeting immune-mediated conditions, with its lead candidate expected to enter Phase 1 clinical development by early Q3 2026.
- The acquisition aims to strengthen Biogen’s immunology pipeline and expand into new disease areas, with Biogen set to lead the development, manufacturing, and commercialization of RayThera’s assets post-closing.
- The transaction is subject to customary closing conditions and regulatory approvals, with completion anticipated in the third quarter of 2026.
- Both companies emphasize the strategic fit and potential for rapid advancement of RayThera’s innovative immunology assets under Biogen’s global development capabilities.
